Understanding Managed Care’s Focus On Prescription Drug Spending
Although managed care began with a focus on physician and hospital services, this focus has shifted in recent years towards [...]
US Hospital Spending Report: Remdesivir Takes the Lead
A recently spending report released by Vizient shows that Remsdesivir, the COVID-19 treatmetn by Gilead Sciences Inc, was the medicine [...]
Congress Pursuing Price Setting Measures that May Not Benefit Patients
In a new PhRMA article, Nicole Longo argues that Congress is starting off the year on a wrong foot with [...]
Michigan Attorney General Seeks Investigation Regarding Eli Lilly’s Exorbitant Insulin Prices
The Michigan Attorney General has asked the courts to approve a formal investigation into Eli Lilly’s excessive insulin prices. The [...]
States Can Help Lower Medicine Costs for Patients
Medicine costs for patients have spiked in the past few years, especially for patients with deductibles who often pay the [...]
Forbes: 2022 Economy, Politics, and Drug Pricing Legislation Predictions
In a Forbes piece published early this month, Joshua Cohen makes predictions about the economy, politics, and drug pricing reform [...]
Pfizer, Gilead, and Vertex Raise Prices on Blockbuster Drugs
Major pharmaceutical companies are hiking prices on their blockbuster drugs for 2022. Pfizer is spiking the price of its cancer [...]
Cancer Patients Save Money on Medication Due to ‘Skinny Labeling’
A new study finds that applying a ‘skinny label’ to the generic cancer drug Gleevec made the medicine available for [...]
Integrated Prescription Discount Card Pricing Plan from Express Scripts
The new Right Price offering by Express Scripts automatically applies prescription discount card savings into the price at the point [...]
Drug Makers Raise Prices of Hundreds of Medications by 4.9% for 2022
Data from 46Brooklyn Research shows that drugmakers have raised the cost of 460 drugs by a median of 4.9%. These [...]
Express Scripts Integrates Member Benefits and Rx Discount Card Pricing
Express Scripts has unveiled its new Right Price program, which lets members effortlessly get savings on prescription drugs by automatically [...]
ICER’s First Scorecard Finds Lack of Transparency of Drug Coverage Policies
The Institute for Clinical and Economic Review (ICER) reviewed barriers to fair access to fairly priced drugs, but found difficulties [...]
JAMA Network Open Article Highlights the Plight of the Uninsured as Drug Costs Soar
A recent article published in JAMA Network Open highlights one major healthcare spending trend: the uninsured. An increase in concentration [...]
[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found [...]
Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with [...]
Will Mark Cuban’s PBM Deliver on Pricing Promises?
Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
CEVR Director Publishes Article on Improving Data Dashboards for Drug Value Assessments
Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center Peter Neumann [...]
Pelosi’s Politicking Leads to Drug Pricing Deal
After 15 years, Democrats have managed to advance drug pricing legislation. House Speaker Nancy Pelosi unexpectedly opposed Medicare negotiation in [...]
PBMs Collect Millions in Missing Ohioan Medicaid Funds Amid Clawback Questions
According to Ohio Medicaid Director Maureen Corcoran at a legislative watchdog hearing, pharmacy benefit managers (PBMs) have collected millions of [...]
Patients Rising Initiative Issues Statement on Federal Healthcare Programs and Payer Coverage
The Patient Access and Affordability Project Patients Rising Project, a Patients Rising program, recently issued a statement regarding federal programs [...]
Democrats’ Pricing Legislation Insufficient; PhRMA’s Criticism of Policies Unwarranted
Attempts to reduce drug costs via policy changes are insufficient. Despite the relatively small scale of new legislation, including allowing [...]
PBM Transparency Reform Prompts New Coalition and Low-Cost Startups
Pharmacy benefit management (PBM) companies have faced widespread criticism as high drug costs continue to burden patients. The outcry has [...]